Skip to main content
Premium Trial:

Request an Annual Quote

Exagen Diagnostics Raises $5.4M in Series A Financing

NEW YORK, Jan. 14 (GenomeWeb News) - Exagen Diagnostics has raised more than $5.4 million in a series A financing round, the company said today. Lead investor Tullis-Dickerson was joined by vSpring Capital and Wasatch Venture Fund.

 

Exagen, based in Albuquerque, N.M., uses computational methods to develop genomic markers. It is currently validating prognostic marker sets for breast cancer and hepatitis C that aim to guide treatment decisions.

 

The company was founded in 2002 as a spinoff from Quasar International. It has adapted a computational method used by Quasar to find defects in automotive parts to analyze large amounts of genomic data. Exagen plans to license its genomic marker sets to large diagnostic laboratories.

 

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.